Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Richard Sloan from the University of Michigan was first to document what is referred to as the "accrual anomaly". His 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones.
Sight Sciences's Sloan Ratio for the quarter that ended in Mar. 2026 was -10.80%.
As of Mar. 2026, Sight Sciences has a Sloan Ratio of -10.80%, indicating there is a warning stage of accrual build up.
Sight Sciences (NAS:SGHT) Sloan Ratio % Explanation
A former University of Michigan researcher, Richard Sloan's 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones. In fact, for the 40-year period between 1962 and 2001, buying the lowest accrual companies and shorting the highest accrual companies resulted in an average annual compounded return of 18%, more than double the S&P 500's 7.4% annual return over the same period.
If the Sloan Ratio is between -10% and 10%, the company is in the safe zone and there is no funny business with accruals.
If the Sloan Ratio is less than between -25% and -10% on the negative side, and between 10% and 25% on the positive side, this is a warning stage of accrual build up.
If the Sloan Ratio is less than -25% or greater than 25%, and this ratio is consistent over several quarters or even years, be careful. Earnings are highly likely to be made up of accruals.
As of Mar. 2026, Sight Sciences has a Sloan Ratio of -10.80%, indicating there is a warning stage of accrual build up.
Sight Sciences Sloan Ratio % Related Terms
Sight Sciences Sloan Ratio % Historical Data
* Premium members only.
The historical data trend for Sight Sciences's Sloan Ratio % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SGHT vs TMCI, TLSI, SENS: Sloan Ratio % Comparison
For the Medical Devices subindustry, Sight Sciences's Sloan Ratio %, along with its competitors' market caps and Sloan Ratio % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sight Sciences Sloan Ratio % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Sight Sciences's Sloan Ratio % distribution charts can be found below:
* The bar in red indicates where Sight Sciences's Sloan Ratio % falls into.
Earnings contain a lot of non cash earnings which is called accruals. The Sloan ratio is a way to identify firms with low non-cash or accrual-derived earnings relative to their cash flow.
Sight Sciences's Sloan Ratio for the fiscal year that ended in Dec. 2025 is calculated as
Sight Sciences's Net Income for the trailing twelve months (TTM) ended in Mar. 2026 was -11.941 (Jun. 2025 ) + -8.169 (Sep. 2025 ) + -4.162 (Dec. 2025 ) + -12.98 (Mar. 2026 ) = $-37.25 Mil.
Sight Sciences's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 was -7.543 (Jun. 2025 ) + -8.719 (Sep. 2025 ) + -1.827 (Dec. 2025 ) + -7.029 (Mar. 2026 ) = $-25.12 Mil.
Sight Sciences's Cash Flow from Investing for the trailing twelve months (TTM) ended in Mar. 2026 was -0.21 (Jun. 2025 ) + -0.17 (Sep. 2025 ) + 0.156 (Dec. 2025 ) + -0.06 (Mar. 2026 ) = $-0.28 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sight Sciences (SGHT) has a Sloan Ratio % of -10.80% as of Mar. 2026. Sloan ratio measures earnings quality based on the amount of accruals. View historical data on Sight Sciences and its competitors.
Is Sight Sciences' Sloan Ratio % too high?
Sight Sciences' current Sloan Ratio % is -10.80%. Overall, Sight Sciences has a GF Score™ of 72/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Sight Sciences' Sloan Ratio % compare to TMCI and TLSI?
Sight Sciences' Sloan Ratio % of -10.80% can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Sloan Ratio % for a Medical Devices & Instruments company?
A good Sloan Ratio % depends on the Medical Devices & Instruments industry context. However, Sloan Ratio % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Sloan Ratio % mean?
A high Sloan Ratio % can signal that a stock is expensive relative to its fundamentals. Sloan ratio measures earnings quality based on the amount of accruals. View historical data on Sight Sciences and its competitors. Sight Sciences's current Sloan Ratio % is -10.80%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sight Sciences stock overvalued right now?
Based on GuruFocus' analysis, Sight Sciences (SGHT) is currently considered Modestly Overvalued. The stock's GF Value™ is $4.53, compared to a current price of $5.27 — trading 16.3% above its estimated fair value. The current Sloan Ratio % is -10.80%. Sight Sciences' overall GF Score™ is 72/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Sloan Ratio % calculated?
Sloan Ratio % is calculated from a company's financial statements. For Sight Sciences (SGHT), the current Sloan Ratio % is -10.80% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sight Sciences (SGHT) Overvalued in 2026?
Based on GuruFocus' analysis, Sight Sciences stock appears to be overvalued.
The current stock price of $5.27 is trading 16.3% above its estimated GF Value™ of $4.53.
GuruFocus considers Sight Sciences to be Modestly Overvalued.
Key valuation signals for SGHT:
Sloan Ratio %: -10.80%
GF Value™: $4.53 vs. price of $5.27 (16.3% above fair value)
No single metric tells the full story. See the SGHT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sight Sciences Inc is an ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. The company operates through two segments: Interventional Glaucoma, which generates the majority of revenue and includes the OMNI Surgical System family of products and the SION Surgical Instrument used in minimally invasive glaucoma surgery to reduce intraocular pressure in adult patients with open-angle glaucoma; and Interventional Dry Eye, which includes the TearCare System, an interventional device designed to melt and facilitate the removal of meibomian gland obstructions and restore gland functionality in adult patients with evaporative dry eye disease.
72GF Score
Get the complete analysis for SGHT
Sloan Ratio % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SGHT has been successfully added to your 
